美国 · 平台与数据 · TipRanks
PegBio’s Paidakang Included in China’s 2026 NRDL
详细摘要
PegBio Co., Ltd. Class H ( ($HK:2565) ) has issued an announcement. PegBio is an innovative-drug developer focused on metabolic diseases; its first marketed ...
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.tipranks.com)



